DNLI
Denali Therapeutics Inc.
$26.69
+0.38 (+1.44%)
At close · Jul 8
Market Cap
$4.24B
Shares
158,709,737
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.69
Open$26.08
Day$25.56–26.73
52W$12.58–26.80
Avg vol 30d1.8M
Short int15.4M · 9.7% float · 8.4d
Short vol71%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+40%
above
Price vs 50-day avg
+25%
above
RSI (14)
78
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+37%
trailing
6-month return
+47%
trailing
YTD return
+62%
this year
Relative strength
+40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $21 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
5 of 270 funds reported for Jun 30 · net +11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.71% of float · ▲ +2.8% MoM · 8.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
270 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
EPS growth
−16%
Y/Y
Free cash flow
$-422.1M
Balance sheet
$205.3M
net cash
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 7, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+40%
Bullish
Price vs 50-day avg
+25%
Bullish
RSI (14)
78
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $21 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
5 of 270 funds reported for Jun 30 · net +11 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.71% of float · ▲ +2.8% MoM · 8.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
270 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $13
Now $27 · 99%
52-wk high $27
vs 200-day avg +40%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNLI
this stock
Denali Therapeutics Inc.
|
$4.24B | +61.7% | — | — | 9.7% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNLI | +3.8% | +36.6% | +47.4% | +3.8% | +61.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +4.0% | +35.8% | +39.9% | +4.0% | +52.4% |